Daniel Wacker, PhD
img_Daniel Wacker
ASSISTANT PROFESSOR | Pharmacological Sciences
Research Topics
Addiction, Alzheimer's Disease, Drug Design and Discovery, Membrane Proteins/Channels, Neuroscience, Neurotransmitters, Opioid/Cannabinoid Receptors, Pain, Receptors, Signal Transduction, Structural Biology, Transporters
Multi-Disciplinary Training Area
Disease Mechanisms and Therapeutics (DMT), Neuroscience [NEU]

BSc, MSc, University of Munich

PhD, The Scripps Research Institute

Postdoc, University of North Carolina at Chapel Hill

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.

Below are financial relationships with industry reported by Dr. Wacker during 2023 and/or 2024. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Consulting or Other Professional Services Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership

  • Otsuka Pharmaceutical Co., Ltd.
  • Pangea Botanica
  • Longboard Pharmaceuticals
  • Ocean Bio Limited

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.